Pharmaceutical Executive

By Pharmaceutical Executive PodcastScience Life Sciences

Pharmaceutical Executive episodes

July 23 Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials
In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume to Australia and China, and a pharmacy benefits executive weighs in on why short-term cost thinking is complicating GLP-1 coverage decisions.
4 min
July 22 Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly
In today's Pharmaceutical Executive Daily, Novo Nordisk sues Eli Lilly over GLP-1 advertising it calls misleading, President Trump announces a phased tariff plan for imported generic drugs, and a new commentary argues pharma's AI investment is missing the areas of drug discovery where it matters most.
3 min
July 21 Pharmaceutical Executive Daily: FDA Grants Emergency Use Authorization to Allplex Assay
In today's Pharmaceutical Executive Daily, FDA grants emergency use authorization for Seegene's multiplex PCR assay, a Pfizer medical lead makes the case for continued antiviral use among Covid-19 high-risk patients, and Nuvation Bio's CEO discusses the company's oncology pipeline and philosophy of developing better drugs rather than more of them.
4 min
July 20 Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI factory in life sciences, and FDA clears Consano Bio's IND for a non-opioid biologic targeting chronic sciatica.
4 min
July 17 Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta
In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Executive commentary argues AI-driven patient support still can't replace human connection, and Jasper Therapeutics closes its acquisition of Kira Pharmaceuticals in a deal combining a three-asset immunology pipeline.
3 min
July 16 Pharmaceutical Executive Daily: FDA Approves Lipfendra
In today's Pharmaceutical Executive Daily, FDA approves Merck's Lipfendra as the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly agrees to acquire AtaiBeckley for up to $3.8 billion, and a Pharmaceutical Executive podcast explores how better questions, not just more data, define strong biopharma leadership.
4 min
July 16 Hiring and Fostering Top Talent
Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.
8 min
July 16 The Power of Better Questions: How Great Leaders Balance Risk, Growth and Curiosity
What separates exceptional life sciences leaders from merely capable ones? According to veteran biopharma executive Craig Tooman, it often comes down to one deceptively simple skill: asking the right questions.
In this episode of Leading Edge with Ken Banta, Tooman reflects on the lessons from a career journey spanning clinical, operational, financial and capital market roles, including as the CEO of Silence Therapeutics, and shares how curiosity, disciplined thinking and openness to unexpected opportunities have shaped his leadership philosophy. Joined by Ken Banta, The Vanguard Network founder and CEO, and Pharmaceutical Executive's Mike Christel, the discussion examines how leaders can balance prudent risk management with long-term growth, cultivate cultures where cross-functional teams challenge assumptions and avoid the groupthink that often stifles innovation.
The conversation also explores the changing role of AI in decision-making, why human judgment remains indispensable and how today's CEOs must think differently about funding, scientific strategy and organizational adaptability in an increasingly complex industry.
28 min
July 15 Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer
In today's Pharmaceutical Executive Daily, Steer Bio discusses its regenerative cell therapy platform for cancer-related lymphedema, FDA approves Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor for advanced breast cancer, and Insilico Medicine enters a strategic alliance with Bora Pharmaceuticals worth up to $2.5 billion.
4 min
July 14 Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik
In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.
3 min